“…This also contributes to the high recurrence (rerupture) rates after surgical treatment of up to 94% (in rotator cuff tendon) . In recent years, tissue engineering strategies including the use of porous 3D matrices based on synthetic/natural polymers (e.g., poly( l ‐lactic acid) [PLLA], poly(glycolic acid) [PGA], poly( d , l ‐lactic‐ co ‐glycolic acid) [PLGA], polytetrafluoroethylene, poly(urethane urea), chitin, chitosan‐hyaluronan, and chondroitin sulfate‐hyaluronate acid‐silk fibroin) and extracellular matrices (ECMs; e.g., small intestine submucosa [SIS], dermis, and pericardium]); cells (e.g., mesenchymal stem cells [MSCs], muscle‐derived cells [MDCs], autologous bone marrow mononuclear cells [BMMCs], connective tissue progenitor cells [CTPs], and autologous tenocytes); and biological/physical stimuli (e.g., growth factors, genes, platelet‐rich plasma [PRP], ultrasound, shock wave, and cyclic tensile strain) have been considered as additional therapies to compensate for the inherent limitations of surgical treatment. Growth factors which play a pivotal role in biological processes (i.e., cellular proliferation, migration, adhesion, differentiation; and ECM deposition) to maintain and repair human body have been more frequently used in the reconstruction of musculoskeletal tissues.…”